Overview

Clinical studies of the INVOS™ system demonstrate decreased occurrence of post-operative complications and improved outcomes, including:

Reduced major organ morbidity or mortality (MOMM)([FOOTNOTE=Murkin JM, Adams SJ, Novick RJ, et al. Monitoring brain oxygen saturation during coronary bypass surgery: a randomized, prospective study. Anesth Analg. 2007;104(1):51-58.],[ANCHOR=],[LINK=])

A randomised, controlled clinical study demonstrated that monitoring cerebral rSO2 in coronary artery bypass patients avoids profound cerebral desaturation and is associated with significantly fewer incidences of major organ dysfunction.1

  • Only 3% of the INVOS™ system group experienced MOMM compared to 11% in the control group and compared to 13.4% from the Society of Thoracic Surgeons database.

Reduced length of ICU stay1

Also clinically demonstrated, ICU length of stay for the INVOS™ system group was significantly shorter.1

  • Mean 0.62 day reduction in length of stay, p<0.029.

Reduced incidence of stroke and need for prolonged ventilation([FOOTNOTE=Goldman S, Sutter F, Ferdinand F, Trace C. Optimizing intraoperative cerebral oxygen delivery using noninvasive cerebral oximetry decreases the incidence of stroke for cardiac surgical patients. Heart Surg Forum. 2004;7(5):E376-381.],[ANCHOR=],[LINK=])

The INVOS™ system use on cardiac surgery patients reduced permanent stroke and reduced total time needed for mechanical ventilation.2

  • Incidence of permanent stroke <1% in the INVOS system group compared to 2% in the control group, p<0.0442
  • The study group had greater comorbidities than those in the control group
  • Rated using New York Heart Association (NYHA) classifications
  • Median ventilator time of four hours vs. five hours in the control group, p<0.0016. A significantly greater proportion of the patients in the control group required prolonged ventilation, 10.6% vs. 6.8%, p<0.0014.2